Dextromethorphan / quinidine Oral Capsule [Nuedexta]
RxNorm 1040057
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1040057 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: dextromethorphan / quinidine Oral Capsule [Nuedexta].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDFPrescribable
Semantic Branded Drug Form (SBDF):
Dextromethorphan / quinidine Oral Capsule [Nuedexta]
(Atom ID: 12320937)
TMSYPrescribable
Tall Man Lettering Synonym (TMSY):
Dextromethorphan / quiNIDine Oral Capsule [Nuedexta]
(Atom ID: 12376785)
Patient Education
Dextromethorphan and Quinidine
The combination of dextromethorphan and quinidine is used to treat pseudobulbar affect (PBA; a condition of sudden, frequent outbursts of crying or laughing that can not be controlled) in people with certain conditions such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease; condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken) or multiple sclerosis (a disease in which the nerves do not function properly and patients may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control). Dextromethorphan is in a class of medications called central nervous system agents. The way it works in the brain to treat PBA is not known. Quinidine is in a class of medications called antiarrhythmics. When combined with dextromethorphan, quinidine works by increasing the amount of dextromethorphan in the body.
[Learn More]
* Please review the disclaimer below.